Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer

NCT02172976 is registered in ClinicalTrials.gov with Krankenhaus Nordwest as lead sponsor.

NCT NCT02172976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02172976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer
Lead sponsor
Krankenhaus Nordwest
Phase
Phase 2/3
Overall status
Completed
Start date
November 30, 2014
Completion date
May 31, 2020
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable prancreas carcinoma